MANNKIND CORP Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
MANNKIND CORP (MNKD) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $94.16 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $94.16M.
- 2026-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $109.08M.
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $137.73M.
- 2025-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $275.66M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2026-06-30 | $94.16M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $109.08M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $137.73M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $275.66M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $166.78M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $172.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $170.96M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |